These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21829138)

  • 1. The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young children.
    Karron RA; Casey R; Thumar B; Surman S; Murphy BR; Collins PL; Schmidt AC
    Pediatr Infect Dis J; 2011 Oct; 30(10):e186-91. PubMed ID: 21829138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.
    Englund JA; Karron RA; Cunningham CK; Larussa P; Melvin A; Yogev R; Handelsman E; Siberry GK; Thumar B; Schappell E; Bull CV; Chu HY; Schaap-Nutt A; Buchholz U; Collins PL; Schmidt AC;
    Vaccine; 2013 Nov; 31(48):5706-12. PubMed ID: 24103895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.
    Karron RA; Thumar B; Schappell E; Surman S; Murphy BR; Collins PL; Schmidt AC
    Vaccine; 2012 Jun; 30(26):3975-81. PubMed ID: 22178099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled, phase 1/2a study of the safety and immunogenicity of a live, attenuated human parainfluenza virus type 3 vaccine in healthy infants.
    Bernstein DI; Falloon J; Yi T
    Vaccine; 2011 Sep; 29(40):7042-8. PubMed ID: 21782874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.
    Belshe RB; Newman FK; Anderson EL; Wright PF; Karron RA; Tollefson S; Henderson FW; Meissner HC; Madhi S; Roberton D; Marshall H; Loh R; Sly P; Murphy B; Tatem JM; Randolph V; Hackell J; Gruber W; Tsai TF
    J Infect Dis; 2004 Dec; 190(12):2096-103. PubMed ID: 15551207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation.
    Skiadopoulos MH; Surman SR; St Claire M; Elkins WR; Collins PL; Murphy BR
    Virology; 1999 Jul; 260(1):125-35. PubMed ID: 10405364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
    Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
    J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children.
    Gomez M; Mufson MA; Dubovsky F; Knightly C; Zeng W; Losonsky G
    Pediatr Infect Dis J; 2009 Jul; 28(7):655-8. PubMed ID: 19483659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.
    Karron RA; Belshe RB; Wright PF; Thumar B; Burns B; Newman F; Cannon JC; Thompson J; Tsai T; Paschalis M; Wu SL; Mitcho Y; Hackell J; Murphy BR; Tatem JM
    Pediatr Infect Dis J; 2003 May; 22(5):394-405. PubMed ID: 12792378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A replication-incompetent influenza virus bearing the HN glycoprotein of human parainfluenza virus as a bivalent vaccine.
    Kobayashi H; Iwatsuki-Horimoto K; Kiso M; Uraki R; Ichiko Y; Takimoto T; Kawaoka Y
    Vaccine; 2013 Dec; 31(52):6239-46. PubMed ID: 24144478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.
    Newman JT; Riggs JM; Surman SR; McAuliffe JM; Mulaikal TA; Collins PL; Murphy BR; Skiadopoulos MH
    J Virol; 2004 Feb; 78(4):2017-28. PubMed ID: 14747566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy.
    Greenberg DP; Walker RE; Lee MS; Reisinger KS; Ward JI; Yogev R; Blatter MM; Yeh SH; Karron RA; Sangli C; Eubank L; Coelingh KL; Cordova JM; August MJ; Mehta HB; Chen W; Mendelman PM
    J Infect Dis; 2005 Apr; 191(7):1116-22. PubMed ID: 15747247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human parainfluenza virus 3 vaccine candidates attenuated by codon-pair deoptimization are immunogenic and protective in hamsters.
    Afroz S; Saul S; Dai J; Surman S; Liu X; Park HS; Le Nouën C; Lingemann M; Dahal B; Coleman JR; Mueller S; Collins PL; Buchholz UJ; Munir S
    Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2316376121. PubMed ID: 38861603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.
    Belshe RB; Newman FK; Tsai TF; Karron RA; Reisinger K; Roberton D; Marshall H; Schwartz R; King J; Henderson FW; Rodriguez W; Severs JM; Wright PF; Keyserling H; Weinberg GA; Bromberg K; Loh R; Sly P; McIntyre P; Ziegler JB; Hackell J; Deatly A; Georgiu A; Paschalis M; Wu SL; Tatem JM; Murphy B; Anderson E
    J Infect Dis; 2004 Feb; 189(3):462-70. PubMed ID: 14745704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children.
    Karron RA; Wright PF; Hall SL; Makhene M; Thompson J; Burns BA; Tollefson S; Steinhoff MC; Wilson MH; Harris DO
    J Infect Dis; 1995 May; 171(5):1107-14. PubMed ID: 7751684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers.
    Madhi SA; Cutland C; Zhu Y; Hackell JG; Newman F; Blackburn N; Murphy BR; Belshe RB; Karron RA; Deatly AM; Gruber WC; Bernstein DI; Wright PF
    Vaccine; 2006 Mar; 24(13):2432-9. PubMed ID: 16406170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIV-3 vaccine National Institutes of Health/Aviron.
    Jones T
    Curr Opin Investig Drugs; 2001 Jul; 2(7):890-2. PubMed ID: 11757785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine.
    Skiadopoulos MH; Surman S; Tatem JM; Paschalis M; Wu SL; Udem SA; Durbin AP; Collins PL; Murphy BR
    J Virol; 1999 Feb; 73(2):1374-81. PubMed ID: 9882342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children.
    Bernstein DI; Malkin E; Abughali N; Falloon J; Yi T; Dubovsky F;
    Pediatr Infect Dis J; 2012 Feb; 31(2):109-14. PubMed ID: 21926667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates.
    Liu X; Liang B; Liu X; Amaro-Carambot E; Surman S; Kwong PD; Graham BS; Collins PL; Munir S
    PLoS One; 2020; 15(2):e0228572. PubMed ID: 32045432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.